FOLLOWUS
Clinical observation and mechanism study on treatment of senile dementia with Naohuandan
- Chinese Journal of Integrative Medicine Vol. 11, Issue 2, Pages: 111-116(2005)
- Affiliations：
Department of TCM, The Second Hospital Affiliated to Sun Yet-san University,Guangzhou
- Author bio：
- Funds：Supported by the Research Fund from Guangdong Provincial Administration of TCM (No. A002003002)
DOI：10.1007/BF02836466
CLC：Published：2005，
Scan for full text
Rong-sen, M., Qing-ming, L., Chang-xiu, W. et al. Clinical observation and mechanism study on treatment of senile dementia with Naohuandan., Chin. J. Integr. Med. 11, 111–116 (2005). https://doi.org/10.1007/BF02836466
Meng Rong-sen, Li Qing-ming, Wei Chang-xiu, et al. Clinical observation and mechanism study on treatment of senile dementia with Naohuandan. [J]. Chinese Journal of Integrative Medicine 11(2):111-116(2005)
Rong-sen, M., Qing-ming, L., Chang-xiu, W. et al. Clinical observation and mechanism study on treatment of senile dementia with Naohuandan., Chin. J. Integr. Med. 11, 111–116 (2005). https://doi.org/10.1007/BF02836466 DOI：
Meng Rong-sen, Li Qing-ming, Wei Chang-xiu, et al. Clinical observation and mechanism study on treatment of senile dementia with Naohuandan. [J]. Chinese Journal of Integrative Medicine 11(2):111-116(2005) DOI： 10.1007/BF02836466.
摘要
Objective: To observe the therapeutic effect and mechanism of Naohuandan (NHD) in treating senile dementia (SD).Methods: Clinical study: Fifty-eight patients with SD
whose diagnosis conforms to the Diagnostic Standard of DSM-IV issued by American Association of Psychiatry
were enrolled and randomly assigned into two groups. The 30 patients in the treated group were treated with NHD
4 capsules each time
3 times daily. The 28 patients in the control group were treated with Piracetam
1. 6 g each time
3 times daily. The therapeutic course for both groups was 3 months. The therapeutic efficacy was estimated and compared by comprehensive scores of memory and cognition
scores of Mini-mental State Examination (MMSE) and Activities of Daily Living (ADL). Experimental study: Rats were divided into the control group
the model group and the high-dosage and low-dosage NHD treated groups. The protective effect of NHD on the per-oxidative damage of hippocampal neurons in β-amyloid protein induced SD model was observed and the related criteria were determined.Results: Clinical study showed that both NHD and Piracetam could improve the clinical symptoms of patients
the two medicines showing insignificant difference in total effective rate. But NHD was better in elevating MMSE score and lowering ADL score in patients than Piracetam (P< 0.05 andP<0.01). Experimental study showed that (1) 24 and 72 hrs after modeling
the activity of SOD and GSH were lower and the level of MDA higher in the model group than those in the control group (P<0.05 orP<0. 01). Compared with the model group at the corresponding time points
in the high-dosage NHD group
SOD and GSH were higher
MDA was lower (P<0. 05 orP<0. 01); but in the low-dosage NHD group
SOD at the 72th hr was higher (P<0.05) and MDA at 24th and 72th hrs was lower (P<0.01). And most of the criteria in the high-dosage NHD group was improved better than that in the low-dosage NHD group. (2) The survival rates of neurons in various groups were not different significantly (P>0.05) 24 hrs after modeling
but that in the high-dosage NHD group was significantly higher than that in the model group (P<0.01) and in the low-dosage NHD group 72 hrs after modeling(P<0.05).Conclusion: NHD is an effective Chinese herbal preparation for treatment of SD
and its mechanism is related with its inhibition on peroxidative injury and protection on neurons.
Abstract
Objective: To observe the therapeutic effect and mechanism of Naohuandan (NHD) in treating senile dementia (SD).Methods: Clinical study: Fifty-eight patients with SD
whose diagnosis conforms to the Diagnostic Standard of DSM-IV issued by American Association of Psychiatry
were enrolled and randomly assigned into two groups. The 30 patients in the treated group were treated with NHD
4 capsules each time
3 times daily. The 28 patients in the control group were treated with Piracetam
1. 6 g each time
3 times daily. The therapeutic course for both groups was 3 months. The therapeutic efficacy was estimated and compared by comprehensive scores of memory and cognition
scores of Mini-mental State Examination (MMSE) and Activities of Daily Living (ADL). Experimental study: Rats were divided into the control group
the model group and the high-dosage and low-dosage NHD treated groups. The protective effect of NHD on the per-oxidative damage of hippocampal neurons in β-amyloid protein induced SD model was observed and the related criteria were determined.Results: Clinical study showed that both NHD and Piracetam could improve the clinical symptoms of patients
the two medicines showing insignificant difference in total effective rate. But NHD was better in elevating MMSE score and lowering ADL score in patients than Piracetam (P< 0.05 andP<0.01). Experimental study showed that (1) 24 and 72 hrs after modeling
the activity of SOD and GSH were lower and the level of MDA higher in the model group than those in the control group (P<0.05 orP<0. 01). Compared with the model group at the corresponding time points
in the high-dosage NHD group
SOD and GSH were higher
MDA was lower (P<0. 05 orP<0. 01); but in the low-dosage NHD group
SOD at the 72th hr was higher (P<0.05) and MDA at 24th and 72th hrs was lower (P<0.01). And most of the criteria in the high-dosage NHD group was improved better than that in the low-dosage NHD group. (2) The survival rates of neurons in various groups were not different significantly (P>0.05) 24 hrs after modeling
but that in the high-dosage NHD group was significantly higher than that in the model group (P<0.01) and in the low-dosage NHD group 72 hrs after modeling(P<0.05).Conclusion: NHD is an effective Chinese herbal preparation for treatment of SD
and its mechanism is related with its inhibition on peroxidative injury and protection on neurons.
关键词
senile dementiaNaohuandanamyloid proteinperoxidative injury
Keywords
senile dementiaNaohuandanamyloid proteinperoxidative injury
references
Mack JL, Whitehouse PJ. Quality of life in dementia: State of The Art-Report of the International Working Group for Harmonization of Dementia Drug Guidelines and the Alzheimer’s Society Satellite Meeting. Alzheimer Dis Assoc Disord 2001; 15(2): 67–71.
John C, Morris MD. Dementia update 2003. Alzheimer Dis Assoc Disord 2003; 17(4): 245–258.
Lu HC, Chen RM, Jian WC, et al. Cytotoxic and antioxidant effect of the water extract of the traditional Chinese herb Gusuibu (Drynaria fortunei) on rat osteoblasts. J Formos Assoc 2001; 100(6): 383.
Miao MS, Sun YH, Fang XY. Anti-oxidative effect of rehmannia polysaccharides. Chin J Inform TCM 2002; 9(10): 32–33.
American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 4th ed. (DSM2 IV). Washington, DC: American Psychiatric Association, 1994: 143.
Fu RJ. Standard for diagnosis, syndrome typing and therapeutic effect evaluation of senile dementia (draft). J TCM 1991; 32(2): 56.
Miao HL, Zhu YL, editors. Convalescence and treatment of stroke. Beijing: Huaxia Publishing House, 1996: 42–45.
Zheng GC, editor. Brain aging and senile dementia. Shanghai: Shanghai Publishing House of Scientific and Technologic Literature, 1995: 224–233.
Lustbader JW, Cirilli M, Lin C, et al. ABAD directly links Aβ to mitochondrial toxicity in Alzheimer’s disease. Science 2004; 304: 448–452.
Wang ZH, Yin ZK, Huang HB, et al. Protective effect of propofol against acute renal ischemia/reperfusion caused lipid peroxidation injury. J Clin Anesthesiol 2001: 17(1): 619–621.
0
Views
409
Downloads
1
CSCD
- Meta-XMLDownload
- BibTeXDownload
- EndnoteDownload
- RefMan Download
- NoteExpressDownload
- NoteFirstDownload
Publicity Resources
Related Articles
Related Author
Related Institution
- Address：1 Caochang, xiyuan, Beijing, People's Republic of China Postal code：100091
- Tel：010-62886827, 62877592 Fax：010-62874291
- Technical support is provided by Beijing Founder electronics co., LTD 京ICP备05067934号-1
京公网安备11010802024621 - It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
- Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.
